We studied the immunomodulating effect of withdrawal of immunosuppression with cyclosporin A (CsA) in 42 patients with leukemic relapse of chronic myelogenous leukemia (CML) (n ‫؍‬ 24), acute myeloid leukemia (AML) (n ‫؍‬ 13) and acute lymphoblastic leukemia (ALL) (n ‫؍‬ 5) after allogeneic unmanipulated bone marrow (BMT) or peripheral blood stem cell transplantation (PBSCT). Response to CsA withdrawal was monitored molecularly by the polymerase chain reaction for elimination of CML cells containing the bcr-abl messenger RNA (mRNA) transcript (n ‫؍‬ 24), or mll-af4 mRNA transcript characteristic of leukemic cells with a 11q23 chromosomal abnormality (n ‫؍‬ 1). Rapid tapering of CsA resulted in subsequent achievement of cytogenetic remission in 11 of 14 CML patients (79%) who relapsed in early disease phase (n ‫؍‬ 9 cytogenetic relapse, n ‫؍‬ 2 hematological relapse) after a median of 57 days. Three of 13 AML patients and one of five ALL patients achieved complete remission. CsA withdrawal was accompanied by the development of acute graft-versushost disease (GVHD) grade II in most of the 24 patients with CML. Two patients who achieved remission of AML or ALL died from severe GVHD grade III-IV. We calculated a probability of 84% for achieving and remaining in remission with early relapse of CML 4 years after relapse post BMT, whereas patients with AML have only a probability of about 10% of achieving and remaining in remission after 3 years. Patients with advanced CML and ALL had no chance of achieving and remaining in remission in the same time period.
leukemia effect (GVL). Since 1990, it has been known that leukemic relapses after allogeneic transplantation can be successfully treated by the induction of a GVL reaction. 3 Immunotherapies which induce GVL effects are mainly associated with the use of donor leukocyte infusions alone or in combination with interferon alfa, which may result in cytogenetic remissions in patients with CML. [3] [4] [5] In single case studies it has also been reported that abrupt CsA withdrawal can induce complete remission in patients with malignant diseases who relapse after allogeneic BMT. [6] [7] [8] [9] CsA withdrawal is generally used as first-line treatment in patients with leukemic relapse after allogeneic transplant. However, to our knowledge the effectiveness of CsA withdrawal has never been systematically studied.
The aim of this study was to investigate the remissioninducing effect after CsA withdrawal in 42 patients who relapsed after BMT for acute or chronic leukemia. Response to treatment with CsA withdrawal was monitored for patients with CML cytogenetically for the Philadelphia chromosome and molecularly by the detection of bcr-abl transcripts. The detection of bcr-abl transcripts by the reverse-transcription polymerase chain reaction (RT-PCR) after transplantation is associated with an increased risk of relapse in patients with CML. 10 Furthermore, an AML patient with a 11q23 chromosomal abnormality in relapse after BMT was monitored by RT-PCR for this specific chimeric gene product after CsA withdrawal. In all patients who achieved a complete response, chimeric status was studied by PCR for variable numbers of tandem repeats (VNTRs).
Materials and methods

Patients
We retrospectively studied 42 patients with CML (n = 24), AML (n = 13) and ALL (n = 5) who had relapsed between February 1987 and December 1997 after allogeneic transplantation with BM (n = 39) or PBSCs (n = 3). Approval for this study was obtained from the Institutional Review Board on Medical Ethics at the Essen University Hospital and written informed consent was obtained from all patients and donors. All patients had an Eastern Cooperative Oncology Group perfomance of 0 (a score of 0 indicates no symptoms, a score of 4 severe disability).
Patient characteristics are shown in Table 1 . Details of the different regimens for myeloablative conditioning used in this study have been previously published. 11 The assessment and grading of acute and chronic GVHD followed the commonly accepted clinical criteria as proposed by Thomas et al. 12 Prevention of acute GVHD was with the standard combination of short-course methotrexate (sMTX) and continuous i.v. CsA, 3 mg/kg/body weight (BW) in 32 patients or CsA alone in 10 patients as published earlier. 1 
CsA withdrawal
All patients who suffered a relapse after BMT were still receiving immunosuppressive therapy with CsA. CsA was withdrawn stepwise within 2 weeks to avoid overwhelming GVHD reactions.
Isolation of genomic DNA and minisatellite PCR
DNA was prepared from peripheral blood mononuclear cells obtained from the donor and the recipient using the phenol/chloroform method before the transplant. 13 After the transplant, DNA was extracted exclusively from the peripheral blood to allow determination of chimerism. Chimerism was analyzed by PCR amplification of variable numbers of tandem repeat (VNTR) polymorphisms using the published method for the human minisatellite region D1S80.
14 In male patients with a female donor chimerism analysis was perfomed by PCR amplification of Y chromosome-specific gene sequences as previously published. 14 
Isolation of RNA and detection of BCR/ABL or MLL/AF4 fusion products
RNA was prepared from peripheral blood cells, BM buffy coat cells, K562 cells and MV411 cells as positive control and extracted by the acid guanidium/phenol/chloroform method. 15 BCR-ABL transcripts were studied in a two-step RT-PCR with nested primers, as previously described. 10 MLL/AF4 gene fusion product was studied in an AML patient with t(4;11)(q21;q23) in a two-step RT-PCR using a multiplex-primer set described by Repp et al. 16 A sensitivity of 1:10 6 was reported for the bcr-abl PCR assay. For the mll-af4 PCR assay we found a sensitivity of 1 :10 5 . The presence of intact RNA and the adequacy of PCR synthesis of complementary DNA was evaluated by single-round PCR with GAPDH or beta-actin sequencespecific primers. 16 In all patients with CML the Philadelphia translocation was demonstratable by bone marrow cytogenetic analysis prior to transplant.
Definition of positive and negative PCR assays
PCR assays were performed without knowledge of patient cytogenetic results and hematologic remission status. A positive PCR test required a correct size bcr-abl PCR product, as well as a negative 'blank' and K562 amplifications. A negative assay required a successful beta-actin or GAPDH-PCR amplification, but the absence of a bcr-abl PCR product as well as no amplification of the 'blank' and K562-amplifications. If a positive or negative control did not amplify as expected, the entire panel of patient samples in that amplification 'batch' was disregarded and repeated. No attempt was made to quantify PCR products.
Definition of relapse
Hematological relapse was diagnosed on the basis of standard hematological criteria. Cytogenetic relapse was considered to be present if two or more Ph+ metaphases of at least 20 analyzed metaphases were detected in repeated cytogenetic analyses without evidence of hematologic relapse.
Definition of remission and statistical analysis
Hematologic remission was defined as the return of normal blood counts and bone marrow cellularity in the absence of antileukemic therapy. Cytogenetic remission was considered to be present when all bone marrow metaphases were normal. Molecular remission was defined as the inabilitiy to detect bcr-abl messenger RNA (mRNA) or mll-af4 mRNA transcripts by PCR, as described above.
Comparisons between classified variables were performed by the two-tailed Fisher's exact test. Continuous variables were compared by the Wilcoxon rank-order statistics. Time-to-event estimates were calculated by the productlimit method with censoring of subjects at the last time point at which they were at risk for a given event.
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Results
Patients with CML
Response to CsA withdrawal in CML patients with relapse in an early disease phase (EP): All nine patients in cytogenetic relapse and two of the five patients with chronic disease (CP) responded to CsA withdrawal by achieving complete hematologic and cytogenetic remission. Another patient who relapsed in CP achieved complete hematologic remission. In addition, bcr-abl transcript negativity was documented in eight of 11 complete cytogenetic responders. Five of these 11 complete cytogenetic responders also achieved complete chimeric status, according to VNTR-PCR analysis. All but one patient had received a graft from an HLA-identical donor. Two patients were transplanted with bone marrow from unrelated HLAidentical donors. Further details about response to CsA withdrawal are shown in Table 2 .
Response to CsA withdrawal in CML patients with relapse in an advanced disease phase (AP): Only one of 10 patients relapsing in AP responded to CsA withdrawal with a transient hematologic and cytogenetic remission. Two of the 10 patients in AP were transplanted with PBSCs from HLA partially identical family donors. Three of the eight patients who received BM had HLA partially identical family donors. To control increased cell counts, patients were also treated with chemotherapy consisting either of hydroxyurea alone, or in combination with thioguanine or cytosine arabinoside.
One patient who responded was transplanted with bone marrow from her HLA-identical sibling donor and was diagnosed with myeloid blast crisis before BMT. After achieving a cytogenetic remission, the chimeric BCR-ABL transcript was still detectable and VNTR analysis revealed a mixed chimeric status, which is defined as detection of donor and recipient hematopoetic cells. Three months after achieving complete remission, this patient again developed a cytogenetic relapse, which was followed by extramedullary disease and death 3 months later. All the other patients except one died from disease recurrence. One patient who is still in relapse is scheduled for a second transplant.
Probability of remaining in remission after response to CsA withdrawal in CML patients with relapse in AP:
Three of 11 patients who achieved complete hematologic and cytogenetic remission after CsA withdrawal as treatment for EP recurrence post transplant relapsed again. Two patients who had achieved remission again developed a cytogenetic or hematological relapse 1 and 3.5 years later. One patient who relapsed hematologically developed extramedullary disease. Figure 1 shows estimates of probability for achieving and remaining in remission.
GVHD and toxicity after CsA withdrawal in CML patients: GVHD occurred in almost every patient independent of the type of response. GVHD involved predominantly the skin with the appearance of a diffuse maculopapular rash. Liver involvement with GVHD was noted in seven of 24 patients, whereas gut involvement was observed in only three patients. In two patients with advanced disease, grade III GVHD with generalized erythema occurred, and almost all the other patients developed grades I-II disease. Two patients with acute GVHD grades III-IV developed a pancytopenia with leukocytes Ͻ1000 /l, platelets Ͻ20 000 /l and hemoglobin Ͻ85 g/l. GVHD occurred within 2 weeks of CsA withdrawal. Table 2 depicts GVHD occurrence post allogeneic transplantion.
AML patients
Only three of 13 patients responded to CsA withdrawal and achieved complete remission. All three responding patients were transplanted with BM from unrelated donors.
According to the FAB subclassification, the first patient to respond had AML-M2, and was transplanted in relapse from an unrelated donor with a mismatch at the DQ HLAlocus. Relapse occurred 1 month post BMT while the patient was still receiving immunosuppressive therapy with CsA (1.1 mg/kg/BW/day). Withdrawal of CsA resulted in generalized erythema GVHD grade II. Liver and gut involvement was not observed. Eighteen days after withdrawal of CsA a bone marrow biopsy showed complete remission. In order to control GVHD, prednisolone 1 mg/kg/BW/day was given and CsA was restarted at 1.1 mg/kg/BW/day. Prednisolone and CsA had been tapered within 18 months post BMT. Multiple bone marrow speci- The second patient was transplanted in relapse with PBSC and was also diagnosed with AML FAB M2. Leukemic relapse occurred 3 months post PBSCT while the patient was still receiving immunosuppressive therapy with CsA, 3.3 mg/kg/BW/day and 0.6 mg/kg/BW/day prednisolone.
Withdrawal of CsA resulted in the development of acute GVHD grade II with skin and liver manifestations. CsA and prednisolone were restarted at the same doses as prior to the relapse. A bone marrow biopsy obtained 21 days after CsA withdrawal revealed complete remission. VNTR-PCR analysis performed at the same time initially showed mixed chimerism. One month later, complete transient chimerism was found in the VNTR analysis, which became mixed chimerism a month later. However, 3 months after CsA withdrawal, leukemic relapse reoccurred. This patient died, after a second transplant, from therapy-related toxicity.
The third patient who responded to CsA withdrawal had AML-M5a with a 11q23 chromosomal abnormality resulting from a chromosomal translocation t(4;11) (q21;q23). Relapse occurred 6 months post BMT. CsA was still being administered at a dosage of 1.9 mg/kg/BW/day. After BMT, the patient developed GVHD grade II with principally skin manifestations. After CsA withdrawal, GVHD grades III-IV occurred, with gut, liver and skin manifestations. This patient also suffered from aspergillus pneumonia and died from these complications 2 months post relapse. A bone marrow biopsy obtained 1 month after CsA withdrawal revealed complete remission. PCR assay monitoring the 11q23 chromosomal abnormality by detection of the mll-af4 gene transcript, was positive prior to BMT. PCR tests at 2 and 3 months post BMT were negative for the mll-af4 gene transcript. Six months post BMT and 1 week before diagnosis of leukemic relapse, a routinely performed PCR assay for the hybrid gene was again positive. VNTR-PCR analysis showed a mixed chimeric status. One month post relapse, PCR assay for the 11q23 chromosome abnormality was negative and the chimerism analysis revealed complete chimerism, demonstrating that this patient achieved not only hematological but molecular remission of the AML (Table 3) .
Patients with AML had a probability of 10% for achieving and remaining in remission 3 years (1402 days) after relapse post BMT. Probability of survival for all patients with AML who relapsed after transplant was calculated at 29% after 3 years post relapse (Figure 1 ). 
ALL patients
Four of the five ALL patients in relapse after BMT who had CsA withdrawal had T-ALL, and one patient had c-ALL. Table 4 shows patient characteristics. Only one of the five patients responded to CsA withdrawal and achieved complete remission 24 days after discontinuing CsA. This patient was transplanted in relapse from his HLA-identical brother and again relapsed 30 days post BMT. After CsA withdrawal, GVHD grade IV occurred in this patient with a generalized maculopapular rash, and an increase in bilirubin of over 2 mg/dl. The GVHD was accompanied by pancytopenia. He also developed diarrhoea, and was treated with 8 mg/kg/BW/day prednisolone. CsA was readministered at the same dose of 2.2 mg/kg/BW/day. The patient died 80 days post BMT from severe GVHD, 50 days after diagnosis of relapse. A bone marrow biopsy performed at day 54 post BMT showed complete remission. A simultaneously performed chimerism analysis at day 54 post BMT, revealed complete chimerism by PCR analysis (Table 4 ). All four non-responding patients were treated with chemotherapy, but died of relapse within a few weeks.
Patients with ALL had a poor prognosis, with 0% probability for achieving and remaining in remission or surviving (0%) 565 days after relapse post BMT (Figure 1 ).
Discussion
When leukemia relapses after allogeneic transplantation, discontinuation of immunotherapy is almost always the first action taken. Despite this fact, response rates for this procedure have never, to our knowledge, been sytematically studied. Here, we analyzed the remission-inducing effect of withdrawal of immunosuppression with CsA in 42 patients with relapse of acute and chronic leukemia after BMT or PBSCT.
The rapid tapering of prophylactic immunosuppressive therapy resulted in remission in 11 of 14 patients who relapsed with early CML (79%). All nine patients with cytogenetic relapse of CML, and two patients with hematol-ogical relapse in the chronic phase of CML responded to CsA withdrawal by achieving hematological and cytogenetic remission. The bcr-abl transcript as a molecular marker for CML was no longer detectable in eight of the 11 responders.
However, patients with relapse of advanced CML, and patients with relapse of AML or ALL showed only a poor response to CsA withdrawal. Only three of 13 AML patients (23%) and one of five ALL patients achieved complete remission after discontinuing CsA. All three patients with AML who achieved complete remission had unrelated donors, which might have promoted the antileukemic effect of CsA withdrawal. VNTR analysis revealed a complete chimerism status in these three patients.
In one AML patient with a 11q23 chromosomal abnormality, the mll-af4 gene transcript was no longer detectable by RT-PCR after CsA withdrawal, thus demonstrating a molecular remission in this patient.
Although patients with acute leukemia also received a low dose of chemotherapy with cytosine arabinoside to control the cell count, achievement of complete remission could not be anticipated through the effect of chemotherapy alone. As published recently, chemotherapy without any immunotherapy had no remission-inducing effect in patients with relapse of advanced CML after allogeneic BMT. 18 Where response occurred, complete remission was documented at a median of 55 days (range 24-210) in patients with CML, and 25 days (range 18-35) in patients with AML and ALL after CsA was discontinued. Most case reports concerning CsA withdrawal have reported a similar response period of 45-67 days after withdrawal of CsA until remission was documented, although in one case response time was 220 days. [6] [7] [8] [9] A remission-inducing effect of CsA withdrawal after post-transplant relapse is not only described in patients with CML, but also in patients with ANL and Burkitt's lymphoma. [6] [7] [8] [9] For patients with early CML we calculated a probability of 84% for achieving and remaining in remission after 4 years following relapse post BMT, whereas patients with AML have only a probability of about 10% of achieving and remaining in remission after 3 years. Patients with advanced CML and ALL seem to have an even poorer outcome.
CsA withdrawal was accompanied by acute GVHD in most patients with CML, including those in whom a hematological response was not induced. However, development of GVHD in patients with AML and ALL was mainly seen in patients who responded to the abrupt discontinuation of CsA. However, two of three responders who achieved remission through a GVL effect died from severe GVHD grade III-IV. Thus, this therapy approach involves high therapy-related mortality. This observation is consistent with previously published experiences of CsA withdrawal. 2, 6 The mechanisms by which CsA withdrawal may induce or augment antileukemic activity against residual clonogenic CML cells after allogeneic BMT are currrently not understood. CsA reduces T cell HLA-DR and interleukin-2 receptor expression (IL-2R), 19, 20 breaks self-tolerance, and induces killer cells with specificity against class II MHC (Ia) antigens on both host and tumor cells. [19] [20] [21] Withdrawal of CsA may, therefore, lead to a rebound phenomenon with an increase in the number and activity of T cells, 2 an overexpression of surface antigens such as MHC-, DR antigens and IL2R, and increased cytokine release. Some of these mechanisms which are induced by CsA withdrawal may thus accelerate an inapparent GVL reaction.
The cellular basis of clinical GVL reactions needs further definition, but current evidence points to a role of cytotoxic T cell clones with reactivity against major or minor histocompatibility antigens not shared between donor and recipient. 2 It therefore appears that CsA withdrawal is operating in the antigen presentation as well as in the effector phase of the immune response underlying the GVL effect.
Comparison of response rates to CsA withdrawal and immunotherapy with interferon alfa shows CsA withdrawal to apparently have a higher response rate. Arcese et al 22 reported a response rate of only 42% in CML patients with cytogenetic relapse after BMT to interferon alfa. Higano et al described a cytogenetic response to interferon alfa therapy in six of 18 patients (33%) with relapsed CML in stable disease phase. [23] [24] [25] However, in this study, about 80% of patients in relapse with early CML in an early disease phase responded to CsA withdrawal by achieving complete cytogenetic remission. Similar high response rates to CsA withdrawal are found after donor leukocyte infusions. [3] [4] [5] However, it appears likely that the effect of CsA withdrawal has not been adequately considered in many reports dealing with the treatment of post-transplant relapses. Also, the immunotherapy induced by CsA withdrawal is limited to patients who are still receiving this immunosuppressive therapy. Furthermore, it is often restricted to allogeneic transplants without T cell depletion.
For patients with leukemia relapsing after BMT who are still receiving therapy with CsA, withdrawal of CsA offers the first opportunity of inducing a GVL reaction. This fact is generally accepted, and CsA withdrawal has become part of many therapeutic approaches for patients in relapse after allogeneic transplantation. 18, 26 The resulting GVHD reaction can be very extensive and is associated with a high mortality.
